AlloVir prices public offering of 20M shares at $3.75/share for $75M gross

Kalaris Therapeutics, Inc.

Priced underwritten public offering of 20,000,000 shares at $3.75 per share; gross proceeds of $75.0M.
Net proceeds estimated at $70.2M ($80.7M if underwriters fully exercise 30-day option for 3M additional shares).
Offering expected to close on or about June 26, 2023; underwriters include J.P. Morgan, Morgan Stanley, and BofA.
Shares offered under existing shelf registration; 90-day lock-up for AlloVir executives and directors.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Kalaris Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters valued at $3.75 per share (effective 2023-06-21).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters
Value: $3.75 per share
Effective: 2023-06-21

Exact text from the filing

On June 21, 2023, AlloVir, Inc. (“AlloVir”) entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters (the “Underwriters”) relating to an underwritten public offering of 20,000,000 shares of its common stock, par value $0.0001 per share, at a price to the public of $3.75 per share, less underwriting discounts and commissions.

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-175095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.